|
Volumn 19, Issue 4, 2007, Pages 350-353
|
Off-label use of antipsychotics: Rethinking "off-label"
|
Author keywords
Antipsychotics; Indications; Off label; Recommendations
|
Indexed keywords
ANTIDEPRESSANT AGENT;
ATYPICAL ANTIPSYCHOTIC AGENT;
BENZODIAZEPINE DERIVATIVE;
HALOPERIDOL;
MOOD STABILIZER;
NEUROLEPTIC AGENT;
OLANZAPINE;
PROMAZINE;
PSYCHOTROPIC AGENT;
QUETIAPINE;
RISPERIDONE;
SULPIRIDE;
ADJUVANT THERAPY;
AGITATION;
ALCOHOLISM;
ANXIETY DISORDER;
BIPOLAR DEPRESSION;
BIPOLAR MANIA;
CLINICAL PROTOCOL;
CONFERENCE PAPER;
CONSENSUS DEVELOPMENT;
DEMENTIA;
DRUG EFFICACY;
DRUG INDICATION;
DRUG LEGISLATION;
DRUG TOLERABILITY;
EVIDENCE BASED MEDICINE;
HUMAN;
INFORMATION RETRIEVAL;
LOW DRUG DOSE;
MANIA;
MEDLINE;
MONOTHERAPY;
OFF LABEL DRUG USE;
OLIGOPHRENIA;
PRACTICE GUIDELINE;
PRESCRIPTION;
PSYCHOMOTOR DISORDER;
PSYCHOPHARMACOTHERAPY;
PSYCHOSIS;
SCHIZOPHRENIA;
ANTIPSYCHOTIC AGENTS;
DRUG APPROVAL;
HUMANS;
MENTAL DISORDERS;
TREATMENT OUTCOME;
|
EID: 36448990842
PISSN: 03535053
EISSN: None
Source Type: Journal
DOI: None Document Type: Conference Paper |
Times cited : (8)
|
References (12)
|